Key players in the global epigenetics market, such as
Illumina, Thermo Fisher, Diagenode, Merck Millipore, Abcam, Active Motif, New
England Biolabs, Agilent, Zymo Research, and PerkinElmer, are focusing on
increasing their presence in the high-growth markets through organic as well as
inorganic strategies such as product launches, partnerships, agreements,
collaborations, expansions, and acquisitions.
The growth in epigenetics market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the in the coming years.
According to a press release published by the Tufts Center for the Study of Drug Development in May 2015, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years, and these investments are further expected to increase by 33% over the next five years. This will further drive the use of epigenetics tools.
Know more: https://tinyurl.com/ydblralk
Illumina operates through 26 subsidiaries located in the US, the UK, and other countries in Europe and the Asia Pacific regions. In order to achieve high growth and increase its customer base, the company focuses on organic and inorganic strategies such as product launches, collaborations, and agreements. For instance, in January 2017, Illumina launched a NovaSeq instruments series.
Thermo Fisher is another prominent player in the epigenetics market. The company develops and manufactures high-end analytical instruments, laboratory equipment, software, consumables, reagents, and services for scientific research, analysis, discovery, and diagnostics. It operates in more than 180 countries across North America, Europe, Asia, Middle East, Africa, and Latin America.
Visit: https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html
The growth in epigenetics market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the in the coming years.
According to a press release published by the Tufts Center for the Study of Drug Development in May 2015, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years, and these investments are further expected to increase by 33% over the next five years. This will further drive the use of epigenetics tools.
Know more: https://tinyurl.com/ydblralk
Illumina operates through 26 subsidiaries located in the US, the UK, and other countries in Europe and the Asia Pacific regions. In order to achieve high growth and increase its customer base, the company focuses on organic and inorganic strategies such as product launches, collaborations, and agreements. For instance, in January 2017, Illumina launched a NovaSeq instruments series.
Thermo Fisher is another prominent player in the epigenetics market. The company develops and manufactures high-end analytical instruments, laboratory equipment, software, consumables, reagents, and services for scientific research, analysis, discovery, and diagnostics. It operates in more than 180 countries across North America, Europe, Asia, Middle East, Africa, and Latin America.
Visit: https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html
Comments
Post a Comment